Industries > Pharma > Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne

PUBLISHED: 31 July 2019
PAGES: 170
PRODUCT CODE: PHA0460
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0460 Categories: , Tags: , , , ,

The global macular degeneration and other retinal diseases market is estimated at $14.85bn in 2018 and is expected to grow at a CAGR of 6.7% during the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 176-page report you will receive 110 charts– all unavailable elsewhere.

The 176-page report provides clear detailed insight into the macular degeneration (AMD) and other reginal diseases drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global AMD and Other Retinal Diseases Market forecasts from 2019-2029

• Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Disease Segment from 2019-2029:
• Wet AMD
• Dry AMD
• Diabetic Retinopathy
• Other Retinal Diseases

• Revenue forecasts for Global AMD and Other Retinal Diseases Drugs Market by Product from 2019-2029:
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others

• Revenue forecasts for the Global AMD and Other Retinal Diseases Drugs Market by Region from 2019-2029:
• U.S.
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• Brazil
• Russia
• India
• Rest of the World

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

• Discussion and profiles of the below selected leading companies:
• Acucela, Inc.
• Allergan Plc
• Bayer AG
• F. Hoffman-La Roche, Ltd.
• GlaxoSmithKline Pharmaceuticals, Ltd.
• IVERIC bio, Inc.
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals
• Valent Pharmaceuticals International, Plc

• Analysis of the Drivers, Restraints, Opportunities and Threats of the global AMD and other retinal diseases market

• The report also includes a SWOT and STEP analysis of the global AMD and other retinal diseases market

• Discussion on the pipeline for Wet AMD. Dry AMD and Diabetic Retinopathy

• Key questions answered by this report:
• How is the retinal diseases market evolving and what are the market prospects from 2018?
• What forces stimulate and restrain that market?
• What are the sales figures for retinal diseases?
• How will revenues of retinal diseases segments grow over the forecast period, 2019 to 2029?
• How will individual product sales develop to 2029?
• Which R&D pipeline products are likely to dominate the market in the next ten years, and what are their sales potentials?
• Which submarkets and national markets form the main drivers of the overall world market to 2029?
• How will social, technological, economic and political forces influence regional markets and world-level submarkets?
• How will market shares of top countries change by 2029 – with their revenues – and which regions will lead the market in 2029?
• Who are the leading companies and what are their prospects over the forecasted period?

Visiongain’s study is intended for anyone requiring commercial analyses for the macular degeneration (AMD) and other reginal diseases drugs market. You find data, trends and predictions.

Buy our report today Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029: Wet AMD, Dry AMD, Diabetic Retinopathy, Lucentis, Eylea, Avastin, Visudyne.

Visiongain is a trading partner with the US Federal Government
CCR Ref number KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029


Latest Pharma news

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

READ

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

READ

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

READ

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

READ

Categories

Category